Generalization between benzodiazepine- and triazolopyridazine-elicited discriminative cues

Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system

Rats can be trained to discriminate benzodiazepines (BZ) from vehicle and there is considerable evidence that the stimulus effects of these drugs are mediated by activity at omega (BZ) modulatory sites of the GABAA receptor complex. A number of recent studies, however, have indicated that differences may exist between the discriminative stimulus effects of benzodiazepines and those of certain non-benzodiazepine ligands for the omega (BZ) receptors (e.g. zolpidem, abecarnil). As it is known that several subtypes of omega (BZ) sites are found in the central nervous system, and that drugs such as zolpidem have selectivity for certain subtypes, it is possible that differential stimulus effects may be associated with receptor selectivity. In the present study, correlations were calculated between the potencies of nine compounds with affinity for omega receptors (diazepam, lorazepam, triazolam, clonazepam, alprazolam, zopiclone, suriclone, CL 218, 872 and zolpidem) to substitute for chlordiazepoxide in rats trained to discriminate a dose (5 mg/kg) of this benzodiazepine and the ability of the same compounds to inhibit the binding of [3H]-flumazenil from different structures in the rat central nervous system in vivo. The correlations obtained were: cerebellum 0.46, cortex 0.39, striatum 0.78 (P < 0.05), hippocampus 0.79 (P < 0.05) and spinal cord 0.95 (P < 0.001). These different structures are known to contain different relative concentrations of omega 1 (BZ1) and omega 2 (BZ2) sites with the spinal cord containing the greatest (80%) and cerebellum the lowest (5%) concentration of omega 2 (BZ2) sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of chlordiazepoxide and putative anxiogenics on conditioned suppression in rats

This paper reports two experiments. In Experiment 1, the effects of chlordiazepoxide alone and in combination with a series of putative antagonists at various sites on the GABA/benzodiazepine receptor complex on conditioned suppression of operant behavior in rats were assessed. Response rates during presentation of a stimulus associated with shock (CS responding) and when only positive reinforcement is effective (pre-CS responding) were analysed. Chlordiazepoxide (10 mg/kg) significantly increased CS responding. This effect was significantly antagonised by Ro15-1788 (10 mg/kg) and by picrotoxin (1.5 mg/kg), but not by bicuculline (1.5 mg/kg) or by delta-amino-n-valeric acid (10 or 20 mg/kg). Chlordiazepoxide also significantly, albeit more slightly, increased pre-CS responding and none of the other drugs tested significantly antagonised this action, though Ro15-1788 plus chlordiazepoxide resulted in pre-CS response rates not significantly different from either chlordiazepoxide alone or control. These interactions are discussed in the context of the proposed GABA/benzodiazepine receptor complex with the conclusion that drug effects at the benzodiazepine- and picrotoxin-sensitive channel sites have an important role in mediating anxiolytic action. However, behavioral evidence of an important role for GABAa or GABAb receptors remains very limited. The second experiment studied the intrinsic actions of bicuculline, picrotoxin, and Ro15-1788 on conditioned suppression. Responding during a conditioned stimulus associated with a mild (0.125 to 0.15 mA) electric shock (CS responding) and a control rate of responding (pre-CS responding) were recorded. Bicuculline (1.5 mg/kg) and Ro15-1788 (10 mg/kg) did not significantly affect either response rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of agonists and antagonists at the GABA/benzodiazepine receptor on conditioned suppression in rats

Certain drugs generally regarded as GABA agonists, such as valproate and combinations of muscimol and baclofen, have been reported to produce apparent anxiolytic effects in various animal behavioral tests. The present paper reports two experiments on the effects of these agents on conditioned suppression in rats. In the first study, muscimol (0, 1.25 micrograms/kg or 1 mg/kg), baclofen (0, 1 mg/kg) and combinations of these treatments failed to alleviate conditioned suppression. Experiment Two showed that valproate (200 mg/kg) did attenuate conditioned suppression, and that its effects were antagonised by picrotoxin (1.5 mg/kg), but not by bicuculline (1.5 mg/kg), Ro 15-1788 (10 mg/kg) or by delta-amino-n-valeric acid (10 mg/kg). The findings are discussed in the context of the proposed GABA/benzodiazepine receptor complex, with the conclusion that there is little evidence for a mediating role of GABAa or GABAb receptors in such drug actions, and that the site of valproate action is probably the chloride ion channel associated with the receptor complex.

Chlordiazepoxide and valproate enhancement of saline drinking by nondeprived rats: effects of bicuculline, picrotoxin and Ro15-1788

Drinking of 0.85% saline by nondeprived rats was significantly enhanced by chlordiazepoxide (5 or 10 mg/kg) and by valproate (100 or 300 mg/kg), drug effects being strongest in the earlier parts of a 30-minute test. When given alone, both bicuculline and picrotoxin significantly reduced saline drinking at 2.5 mg/kg, but not 1.5 mg/kg. Administration of valproate at either dose or of chlordiazepoxide (10 mg/kg) completely prevented bicuculline action and 5 mg/kg chlordiazepoxide reduced it. Picrotoxin, however, largely prevented the actions of both chlordiazepoxide and valproate. The increase in saline drinking induced by valproate (300 mg/kg) was also blocked by RO15-1788 (10 or 25 mg/kg). These findings are discussed in the context of the three-site model of the GABA/benzodiazepine receptor complex. It is concluded that drugs acting at the benzodiazepine site or the chloride ion channel affect saline drinking, but that there is little evidence of an important functional role for the GABAa site at present.

Discriminative stimulus properties of midazolam: comparison with other benzodiazepines

Rats (N = 12) were trained to discriminate midazolam (1 mg/kg, IP) from vehicle in a food reinforced operant conditioning procedure. Midazolam, flunitrazepam, diazepam, chlordiazepoxide and pentobarbital showed dose-dependent substitution for midazolam. Buspirone and Ro 15-1788 did not substitute for midazolam. The midazolam cue was dose-dependently antagonized by Ro 15-1788. In rats (N = 12) trained to discriminate chlordiazepoxide (3 mg/kg, IP) from vehicle midazolam, flunitrazepam, diazepam and chlordiazepoxide substituted completely and dose dependently for chlordiazepoxide. The relative potency of chlordiazepoxide and diazepam was three times less in the midazolam-trained animals than in the chlordiazepoxide-trained animals. Response rate and latency data further support the main finding that the midazolam cue is similar, but not identical to the cue of classical benzodiazepines.

Discriminative stimulus properties of CGS 9896: interactions within the GABA/benzodiazepine receptor complex

Male rats were trained to discriminate the stimulus effects of CGS 9896 (30.0 mg/kg) from its vehicle. Once trained, discriminative performance was observed to be dose-responsive in the 3.75-30.0 mg/kg range and analysis of the dose-response curve generated an ED50 of 6.44 mg/kg. Generalization testing with chlordiazepoxide and pentobarbital produced CGS 9896-appropriate responding, whereas administration of the GABA agonists SL 75 102 resulted in 75% (intermediate) generalization to the CGS 9896 discriminative stimulus. Although full antagonism of the CGS 9896 cue was obtained following administration of Ro15-1788 and pentylenetetrazole, the inverse agonist DMCM failed to provide complete antagonism. These results suggest that the discriminative properties of CGS 9896 are consistent with its activity as a benzodiazepine receptor agonist.

Comparison of discriminative stimuli produced by full and partial benzodiazepine agonists: pharmacological specificity

Benzodiazepines produce discriminative stimuli that are stereospecific and antagonized by specific benzodiazepine receptor antagonists. The potency of these stimuli correlate with the ability of these compounds to bind to the benzodiazepine receptor complex. These data indicate that benzodiazepine stimuli are transduced via the benzodiazepine receptor. The underlying basis of these stimuli is unclear. Results with novel compounds that produce preclinical anxiolytic effects without the sedation and muscle relaxation of the classical benzodiazepines suggest that muscle relaxation may contribute to these stimuli. A direct comparison of discriminative stimuli established on a classical benzodiazepine agonist with the stimuli established on a partial benzodiazepine agonist supports the possibility that the classical benzodiazepine cue is mediated by a muscle relaxant effect, while the partial agonist cue is related to the anxioselectivity of the compound.

Behavioral evidence for the role of noradrenaline in putative anxiolytic and sedative effects of benzodiazepines

The effects of clonidine on the antianxiety and sedation of benzodiazepines (BZD) were assessed respectively in rats trained in a two-lever diazepam cue discrimination procedure and in single-lever fixed-ratio (FR) water-reinforced performance. Clonidine (10-60 micrograms/kg) significantly shifted to the left the dose-effect curves of diazepam in the discrimination paradigm. This treatment also shifted generalization dose-effect curves of the diazepam cue to chlordiazepoxide and CL 218,872 to the left in the drug discrimination procedure. The diazepam cue was antagonized in a dose-related manner by Ro 15-1788, but not by bicuculline. Clonidine also potentiated the rate-decreasing effects of diazepam on the FR schedule when the dose of diazepam was increased to 0.3 mg/kg, but not the milder rate-decreasing effect of CL 218,872 until the dose of CL 218,872 was increased to 10 mg/kg. The potentiating effects of clonidine on the stimulus control and depression of diazepam were antagonized by yohimbine. Yohimbine (1.0 mg/kg) also significantly shifted the dose-effect curve of diazepam cue to the right. Bicuculline (3 mg/kg) completely antagonized the rate-decreasing effect of diazepam (1 mg/kg), but significantly potentiated the rate-suppressant effect of clonidine (10 micrograms/kg). These results suggest that the central noradrenaline (NA) system may be involved not only in the antianxiety, but also the sadative action of BZD. The nature of NA involvement in relation to the different subtypes of BZD receptors requires further exploration.

Discriminative stimulus properties of anxiolytic and sedative drugs: pharmacological specificity

In the first set of experiments rats were trained to discriminate a dose of 5 mg/kg chlordiazepoxide from saline. The chlordiazepoxide cue was antagonized by flumazepil (Ro 15-1788) and by CGS 8216, and generalized to a variety of anxiolytic and sedative drugs including the benzodiazepine receptor ligands zopiclone, suriclone, CL 218,872, CGS 9896, and ZK 91296. The novel imidazopyridine hypnotic, zolpidem, which also displaces benzodiazepines from their binding sites, failed to produce high levels of responding on the chlordiazepoxide-associated level except at a dose which greatly reduced rates of lever pressing. In further experiments rats were trained to discriminate a dose of 2 mg/kg zolpidem from saline. This dose produced reductions in response rates but an attempt to establish a lower dose of zolpidem as a discriminative stimulus was largely unsuccessful. Zolpidem-appropriate responding was produced by pentobarbital, chlordiazepoxide, triazolam, CL 218,872, clorazepate, lorazepam, quazepam, and zopiclone but only at doses which reduced response rates. The zolpidem cue was antagonized by flumazepil, CGS 9896, and ZK 91296. While the discriminative stimulus produced by chlordiazepoxide may be related to its anxiolytic action, the zolpidem stimulus is probably more closely associated with sedation. It was also tentatively concluded that the stimulus properties of chlordiazepoxide and zolpidem are produced by activity at different subtypes of benzodiazepine receptors.

Behavioral effects of several new anxiolytics and putative anxiolytics

The behavioral effects of several new anxiolytics and putative anxiolytics were evaluated in two tests sensitive for anxiolytic activity. In the first test, rats were trained to lever-respond for sweetened milk under a multiple variable-interval fixed-ratio (VI-FR) schedule of reinforcement. In the FR component a brief electric shock coincided with the presentation of reward (i.e. conflict procedure). Treatment of these rats with diazepam, tracazolate, CGS-9896, and the pyrimidinylpiperazine derivatives buspirone, gepirone and ipsapirone (TVX Q 7821) significantly increased responding that was suppressed by foot-shock. A common metabolite of the pyrimidinylpiperazines, l-PP, had no affect on punished responding. A second group of rats was trained to discriminate diazepam from saline using a two-lever operant choice procedure. Diazepam-stimulus generalization occurred to CGS-9896, CL 218,872, zopiclone and tracazolate, but not to buspirone, gepirone, ipsapirone or l-PP. It was concluded that while all of the new compounds examined appear to share an anxiolytic effect as demonstrated by their activity in the conflict procedure, the pyrimidinylpiperazine agents do not share discriminative stimulus properties which are common to drugs which act via the benzodiazepine receptor.

Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296

In previous studies the effects of CGS 9896, a pyrazoloquinoline ligand at benzodiazepine receptors, in rats trained to discriminate benzodiazepines from vehicle, have been variable. The present experiment confirmed that this compound produced responding on the drug-lever in rats trained to discriminate 5 mg/kg of chlordiazepoxide from saline, and showed that CGS 9896 did not antagonise the effect of chlordiazepoxide in this test. In contrast, CGS 9896 antagonised the stimulus properties of zolpidem (2 mg/kg), a non-benzodiazepine hypnotic, which displaces benzodiazepines from their binding sites. The drug CGS 9896 also antagonised responding on the drug-lever produced by chlordiazepoxide in rats trained with zolpidem. The beta-carboline, ZK 91296, produced effects similar to those of CGS 9896, giving rise to responding on the drug-lever in rats trained with chlordiazepoxide and antagonising the zolpidem cue. These results demonstrate the mixed agonist-antagonist effects of CGS 9896 and ZK 91296 and suggest that the stimulus properties of chlordiazepoxide and zolpidem may be mediated by different sub-types of benzodiazepine receptors.

Discriminative stimulus properties of oxazepam in the pigeon

Five pigeons were trained to discriminate IM injections of oxazepam (4.0 mg/kg) from vehicle with responding maintained under a fixed-ratio 30 schedule of food delivery. Under test conditions, responding increased in a dose-dependent manner in all pigeons after the administration of other benzodiazepines including diazepam (0.01-1.0 mg/kg), temazepam (0.01-3.0 mg/kg), halazepam (0.1-56.0 mg/kg), and midazolam (0.1-1.0 mg/kg) as well as the barbiturate pentobarbital (2.0-8.0 mg/kg) and the non-benzodiazepine anxiolytic CL 218,872 (1.0-8.0 mg/kg). At the higher doses of each of these compounds, over 80% of responding occurred on the oxazepam-appropriate key. Cocaine (0.5-4.0 mg/kg), bupropion (3.0-56.0 mg/kg) and nortriptyline (3.0-56.0 mg/kg) failed to substitute for oxazepam even at doses that decreased rates of responding. The discriminative stimulus (DS) effects of the lowest doses of oxazepam and CL 218,872 that produced 100% drug-appropriate responding were blocked by the benzodiazepine antagonist Ro 15-1788. This antagonism was reversed by increasing the dose of the agonists. The DS effects of diazepam were antagonized partially by Ro 15-1788 (3 of 5 pigeons), and the antagonism was reversed by higher doses of diazepam in two of these pigeons. The DS effects of pentobarbital were antagonized by Ro 15-1788 in 2 of 5 pigeons, but the blockade was not reversed by higher pentobarbital doses.

A new method for screening anxiolytic drugs in rats

In order to evaluate the anxiolytic action of drugs, a simple experimental procedure using a corridor-type runway was designed. In this apparatus, five food pellets were set in a row on a plastic platform. Rats with one day food-deprivation take a food pellet and then usually return to the start box. The time required to take 5 pellets (total time) and the number of returns were recorded. Diazepam (DZP) at 1-3.2 mg/kg and zopiclone (ZOP) at 10 mg/kg caused decreases in both parameters. These effects were blocked by the benzodiazepine receptor blocker, Ro15-1788, at 10 mg/kg. However, tracazolate failed to produce any change in both parameters. Haloperidol and imipramine prolonged the total time while reducing the number of returns. In contrast to DZP and ZOP, pentetrazol, well known to possess an anxiogenic effect, prolonged the total time. These results suggest that decreases in both the total time and the number of returns produced by DZP and ZOP may be related to their anxiolytic action which is mediated by a benzodiazepine receptor. Therefore, this procedure would be a simple and selective method for detecting benzodiazepine-type anxiolytics.

Midazolam cue in rats: effects of drugs acting on GABA and 5-hydroxytryptamine systems, anticonvulsants and sedatives

The discriminative stimulus effect of midazolam, a short-acting benzodiazepine, was used for testing the effects of related drugs including agents thought to act at different sites in the proposed benzodiazepine receptor complex. Rats were trained in a standard two- bar operant conditioning procedure with food reinforcers delivered on a tandem schedule. The 0.4 mg/kg dose of midazolam used for training was well discriminated, typically yielding about 95% correct responding. There was no generalization to the GABA agonists muscimol and THIP, to the 5-HT antagonists cyproheptadine and methergoline, to buspirone, CGS 9896, ethanol, Ro 5-4864, promethazine, phenytoin sodium or sodium valproate. Muscimol and THIP also failed to potentiate the effects of midazolam. The GABA antagonist bicuculline weakly attenuated the discriminative effect of midazolam without impairing generalization to pentobarbitone, whereas the benzodiazepine inverse agonist FG 7142 did not attenuate the effect of midazolam. The results provide additional evidence for the notable specificity of the midazolam cue but do little to link the behavioural effects of benzodiazepines to GABA or 5- HT systems. Perhaps the potency, efficacy or selectivity of the GABA agonists was inadequate to produce the expected results. Only the effects of bicuculline, and those reported previously for picrotoxin, provided some support for the hypothesis that midazolam cue is mediated by the GABA system.

Comparison of the effects of chlordiazepoxide and CL 218,872 on serum corticosterone concentrations in rats

Fifteen minute exposure to a novel environment plus 120 dB sound stimulation produced a three-fold increase in serum corticosterone concentrations in rats. A low dose of intraperitoneally (IP) administered chlordiazepoxide (CDP) (5 mg/kg) attenuated this response, whereas a higher dose (20 mg/kg) elevated corticosterone concentrations in rats not subjected to sound stress. Parallel results were obtained after intracerebroventricular (ICV) drug administration, with a low dose of CDP (5 micrograms) reducing the sound stress response and higher doses (25 and 50 micrograms) increasing corticosterone concentrations in unstressed animals. Thus, despite the presence of benzodiazepine (BDZ) receptors at every level of the hypothalamic-pituitary-adrenocortical axis, it appears that BDZs alter the activity of this system via an interaction with BDZ receptors in brain. CL 218,872 (2.5-20 mg/kg), a novel non-BDZ anxiolytic compound, did not attenuate the corticosterone elevation produced by sound stimulation, and also failed to alter baseline corticosterone concentrations in unstressed animals. The fact that CL 218,872 is a selective agonist for brain Type I BDZ receptors suggests that BDZs are not influencing corticosterone secretion through an interaction with this BDZ receptor subtype. Furthermore, these results indicate that stress (as measured by pituitary-adrenocortical activation) can be dissociated from anxiety (as measured by conflict paradigms), thus challenging the validity of the corticosteroid stress test as a screening procedure for anxiolytic activity.

Effects of chlordiazepoxide training dose on the mixed agonist-antagonist properties of benzodiazepine receptor antagonist Ro 15-1788, in a drug discrimination procedure

In experiment 1, rats (n = 12) were trained to discriminate the benzodiazepine (BDZ) compound chlordiazepoxide (CDP, 20 mg/kg, IP) from saline in a two-lever food-reinforced procedure, and subsequently were tested for stimulus control with different doses of CDP, Ro 15-1788 (a proposed BDZ receptor antagonist) and Ro 15-1788 plus 20 mg/kg CDP. Ro 15-1788 (0.63-40 mg/kg) dose-dependently antagonized CDP, and induced predominantly saline appropriate responding when administered alone. Thereafter, the same rats were retrained by progressively decreasing the training dose, to discriminate 2.5 mg/kg CDP from saline, and were tested again with the same compounds. Ro 15-1788 (0.16-40 mg/kg) now failed to antagonize CDP (2.5 mg/kg) and increased the percentage of drug-appropriate responding in a dose-related manner when administered alone. In experiment 2, separate groups of rats (n = 10) were similarly trained to discriminate either 15 or 3 mg/kg CDP from saline. Tests with CDP, Ro 15-1788 and Ro 15-1788 plus CDP (either 15 or 3 mg/kg) yielded similar results to experiment 1, suggesting that the training dose effects on generalization and antagonism of Ro 15-1788 were not affected by the manner in which the lower CDP dose acquired drug stimulus control. It is concluded that mixed agonist-antagonist properties are apparent after variations of the BDZ training dose in a drug discrimination procedure.

The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic

Zolpidem is a non-benzodiazepine hypnotic drug which displaces benzodiazepines from their binding sites in different brain structures. Previous work has demonstrated several differences between zolpidem and benzodiazepines, including differences between the stimulus properties of zolpidem and chlordiazepoxide. In the present study the discriminative stimulus properties of zolpidem were analysed by training rats to discriminate between this drug and saline. It was found that stimulus control developed readily with 2 mg/kg but not with 1 mg/kg zolpidem. The effect was dose-related, had a short duration of action and was antagonised by Ro 15-1788. Furthermore, stimulus control produced by zolpidem was associated with marked reductions in rates of responding. Injections of chlordiazepoxide, triazolam, lorazepam, zopiclone, CL 218,872 and pentobarbital produced dose-related responding on the zolpidem-associated lever but haloperidol did not. However, in general, the doses of those drugs which produced drug-lever responding also reduced response rates. It is possible that the above mentioned differences between the discriminative stimulus produced by zolpidem in rats and those produced by other sedatives may be due to a selective action of zolpidem on a sub-type of benzodiazepine binding site.

Benzodiazepine-induced hyperphagia in the nondeprived rat: comparisons with CL 218,872, zopiclone, tracazolate and phenobarbital

Nondeprived male rats were familiarized with 30 min daily access to a highly palatable diet. Clonazepam, midazolam and chlordiazepoxide each produced significant dose-dependent increases in food consumption. Clonazepam was the most potent, and a significant hyperphagic effect was detected following 0.078 mg/kg (IP). Amongst novel non-benzodiazepine anxiolytics, zopiclone and CL 218,872 also produced significant increases in food intake. The smallest doses to produce significant hyperphagia for these two drugs were 10.0 and 2.5 mg/kg (IP) respectively. In contrast, tracazolate caused only a reduction in feeding, evident at 20 and 40 mg/kg (IP). Previous reports indicate that although benzodiazepines, zopiclone and CL 218,872 displace [3H] flunitrazepam binding in rat cerebral cortex preparations, tracazolate enhances the binding. Our results are consistent with the drug-induced hyperphagia depending upon agonist actions at high-affinity benzodiazepine sites. They also provide pharmacological evidence for a dissociation between hyperphagic and anxiolytic drug effects. Phenobarbital (2.5-40.0 mg/kg), like the benzodiazepines, produced a strong stimulation of food intake, indicating that drug action at an alternative site in the benzodiazepine receptor-GABA receptor-chloride channel complex can also lead to hyperphagia.

GABA and the behavioral effects of anxiolytic drugs

Much recent research has shown that benzodiazepine binding sites in the central nervous system are associated with GABA receptors. It is therefore possible that the pharmacological and therapeutic effects of benzodiazepines and drugs with similar profiles are mediated through GABAergic mechanisms. In this paper the evidence is considered for a possible involvement of GABA in the behavioral effects of anxiolytic drugs. There are a number of reports that the behavioral actions of anxiolytics can be antagonised by GABA antagonists such as bicuculline or picrotoxin but there are many contradictory findings and these drugs are difficult to use effectively in behavioral studies. In general, GABA agonists do not exert anxiolytic-like behavioral effects after systemic injection but intracerebral administration of muscimol has been shown to produce benzodiazepine-like actions. Although a number of questions remain unanswered, current evidence does not provide strong support for a role for GABA in the behavioral effects of anxiolytic drugs.

A comparison between chlordiazepoxide and CL 218,872--a synthetic nonbenzodiazepine ligand for benzodiazepine receptors on spontaneous locomotor activity in rats

Spontaneous locomotor activity was investigated in rats treated with chlordiazepoxide (CDP) or CL 218,872, a synthetic nonbenzodiazepine ligand for benzodiazepine receptors. Acute administration of CDP (2.5 mg/kg) increased activity, whereas a higher dose (10 mg/kg) decreased activity. Acute injection of CL 218,872 (2.5-10 mg/kg) produced a significant dose-dependent suppression of locomotor activity, a finding at variance with a previous report that anxiolytic doses of CL 218,872 are devoid of depressant side effects. Chronic pretreatment with CDP or CL 218,872 (10 mg/kg daily for 6 days) produced a tolerance to the sedative effect of CDP (10 mg/kg), but not to the activity suppressant action of CL 218,872 (10 mg/kg).

Benzodiazepine receptor mediated discriminative cues: effects of GABA-ergic drugs and inverse agonists

Rats were exposed to a two-lever drug discrimination procedure using the benzodiazepine (BZ) receptor inverse agonists N'-methyl-beta-carboline-3-carboxamide (FG 7142) or methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM). FG 7142 (30 mg/kg) failed to acquire discriminative stimulus control, although it did suppress responding. The same group of animals was trained successfully to discriminate diazepam (DZP, 2.5 mg/kg) from vehicle. The DZP cue was potentiated by the GABA agonist 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol (THIP, 1,3 mg/kg); THIP alone produced vehicle-appropriate responding. In addition, clonazepam (0.2 mg/kg) and chlordiazepoxide (5 mg/kg) substituted for DZP (with potencies of 7.5 and 0.25 times that of DZP, respectively). In antagonism tests, FG 7142 (5-17.5 mg/kg), methyl-beta-carboline-3-carboxylate (beta-CCM, 2.5 mg/kg) did not effect, bicuculline (2 mg/kg) and DMCM (1 mg/kg) partially blocked, and the BZ receptor antagonist Ro 15-1788 (40 mg/kg) completely blocked the discriminative stimulus effects of DZP. In animals trained to discriminate DMCM (0.2 mg/kg) from vehicle, 95.2% substitution occurred with bicuculline (2 mg/kg); DZP (1-5 mg/kg) completely antagonized DMCM. These results indicate that the DZP cue is mediated by GABA-coupled BZ receptors and that GABA may modulate the efficacy of a BZ at its receptor site. However, since inverse BZ receptor agonists (FG 7142, DMCM and beta-CCM) were, at best, only marginally effective in antagonizing DZP, the DZP cue may be mediated by a distinct subclass of BZ receptors.